The tau theory in Alzheimer’s disease took a hit today after TauRx, one of the leading companies researching this hypothesis, saw its drug when used with…

Merck has shocked ALK-Abello by returning the rights to three sublingual allergy immunotherapy tablets, triggered an 18% drop in the Danish firm's share…

This year will be the year of the woman exec in biotech, no doubt about it.

Kite Pharma has always been focused on engineering a patient’s own T cells to treat their cancer. But now, it’s in-licensed tech to create off-the-shelf T-cell…

Bristol-Myers Squibb is really racking up the cancer pacts as today it pens another deal for its PD-1 checkpoint inhibitor Opdivo (nivolumab)--this time to be…

AstraZeneca and partner Moderna Therapeutics are heading to the lab for the first time together with their experimental cardiometabolic drug AZD8601.

The FDA has granted breakthrough therapy status to J&J and Genmab's Darzalex as a second-line treatment for multiple myeloma, positioning it for a…

Newron Pharmaceuticals has seen a much-needed quick turnaround for its lead Parkinson’s drug as it can now resubmit its candidate in the U.S.--just four months…